Impax Labs Inc (IPXL) 30.33 $IPXL Impax (IPXL) Stock

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 3:05 AM

Impax Labs Inc (IPXL) 30.33 $IPXL

Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 30.33 (+0.81), AGN: 233.51 (+4.96), TEVA: 51.37 (+0.18), AMPH: 16.15 (+0.56)

Upgrade Alert for Impax Laboratories (IPXL)
Comtex SmarTrend(R) - Wed Jun 22, 3:33AM CDT
Impax Laboratories (NASDAQ:IPXL) was upgraded from Underperform to Neutral at BofA/Merrill today. The stock closed yesterday at $28.31 on volume of 3.0 million shares, above average daily volume of 539,000. Potential upside of 70.4% exists for Impax Laboratories, based on a current level of $28.31 and analysts' average consensus price target of $48.25. Impax Laboratories shares should first meet resistance at the 50-day moving average (MA) of $33.81 and find additional resistance at the 200-day MA of $38.86.
IPXL: 30.33 (+0.81)

United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 233.51 (+4.96), IPXL: 30.33 (+0.81), CP.TO: 166.11 (+2.75), WERN: 22.40 (+0.25), CP: 130.22 (+2.86), ASEI: 36.96 (-0.04), IMPV: 46.30 (+1.86), UAL: 45.17 (+0.08)

Look for Shares of Impax Laboratories to Potentially Rebound after Yesterday's 11.26% Sell Off
Comtex SmarTrend(R) - Tue Jun 21, 3:09PM CDT
Impax Laboratories (NASDAQ:IPXL) traded in a range yesterday that spanned from a low of $28.11 to a high of $30.00. Yesterday, the shares fell 11.3%, which took the trading range below the 3-day low of $31.31 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IPXL: 30.33 (+0.81)

Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"

and affiliates of Allergan plc ("Allergan"

for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA"

for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction"

for an aggregate purchase price of $586 million.
IPXL: 30.33 (+0.81), AGN: 233.51 (+4.96)

Impax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 3:10PM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, 2016 at 2:40 p.m. Pacific Time. The conference will be held in Rancho Palos Verdes, CA.
IPXL: 30.33 (+0.81)

Impax Labs reports 1Q loss
Automated Insights - Tue May 10, 5:48AM CDT
HAYWARD, Calif. (AP) _ Impax Laboratories Inc. (IPXL) on Tuesday reported a loss of $10.4 million in its first quarter.
IPXL: 30.33 (+0.81)

Impax Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:40AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March 31, 2016.
IPXL: 30.33 (+0.81)

Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:48AM CDT
A positive Earnings ESP coupled with impressive Zacks Rank has made Impax Laboratories (IPXL) an interesting choice for the investors.
IPXL: 30.33 (+0.81)

Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 30.33 (+0.81), CLSN: 1.29 (+0.01), JAZZ: 145.00 (+2.06)

What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 30.33 (+0.81), CPRX: 0.88 (-0.01), JAZZ: 145.00 (+2.06), XON: 25.20 (+0.55)

Intrexon (XON): Stock Likely to Beat Estimates in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:49PM CDT
Intrexon (XON), which is set to report first-quarter 2016 results on May 10, delivered a positive surprise of 5.56% last quarter.
IPXL: 30.33 (+0.81), FCSC: 0.97 (+0.02), JAZZ: 145.00 (+2.06), XON: 25.20 (+0.55)

Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 30.33 (+0.81), BDSI: 2.39 (+0.06), ENDP: 15.84 (+0.39), JAZZ: 145.00 (+2.06)

What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 30.33 (+0.81), SNTA: 0.31 (unch), JAZZ: 145.00 (+2.06), BIND: 0.40 (-0.01)

What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 30.33 (+0.81), JAZZ: 145.00 (+2.06), PBYI: 33.65 (+2.12)

Inovio (INO): What's in Store for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:03AM CDT
Inovio (INO) is scheduled to report first-quarter 2015 results on May 9, before the opening bell.
IPXL: 30.33 (+0.81), INO: 9.85 (-0.35), JAZZ: 145.00 (+2.06), AZN: 29.29 (+0.59)

What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 30.33 (+0.81), JAZZ: 145.00 (+2.06), HZNP: 17.44 (+0.66), BIND: 0.40 (-0.01)

Impax to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Wed May 04, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 9:20 a.m. Pacific Time. The conference will be held in Las Vegas, NV.
IPXL: 30.33 (+0.81)

Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 47.90 (+0.57), IPXL: 30.33 (+0.81), CNAT: 2.13 (+0.09), JAZZ: 145.00 (+2.06)

What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 47.90 (+0.57), IPXL: 30.33 (+0.81), GWPH: 89.14 (+0.57), JAZZ: 145.00 (+2.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Knob-and-Tube Wiring: A Hidden Hazard Unveiled

Unlocking the Mysteries of Knob-and-Tube Wiring Ever wondered if the wiring in your charming hundred-year-old home might be a ticking time bomb? Welcome to the world of knob-and-tube wiring. This blast from the past might just be hiding in those walls and could spell trouble. The History and Hazards of Knob-and-Tube This wiring system dates back to the 1880s, sticking...

Lily Toxicity in Cats: Urgent Action Matters

Understanding the Severity of Lily Toxicity Ah, lilies. They might look pretty on your dining table, but if you’ve got a feline prowling around your house, these beauties could be a silent cat killer. In the animal-medicine world, this isn’t just another cautionary tale; it's a full-blown call to arms for cat owners. Dr. Ashley Wheatley, a veterinary expert out of...

OlloBot's Emotional AI Robots Connect Beyond Tasks

OlloBot Eyes Emotional Bonds, Not Just Robotics Power Is it just me, or is OlloBot onto something deep with their emotional AI companions? They've set a course that might just redefine how we perceive home robotics. At IFA Berlin 2026, they didn't just strut their technical stuff. Nope, they took it beyond gears and gadgets, turning heads with a robot that does more than...

Perion Acquisition: Affle's Bold Leap in Ad Tech

Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...

Double Down for Veterans Raises $20 Million Goal

Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...

Millions Tune In to 'Dedicate' Premiere in Manila

Gathering for a New Kind of Celebration With a buzz louder than a crowded trading floor on a bull day, folks are flocking to catch the ripple effect of "Dedicate." Over 2 million views already, and it hasn't even hit the major radar yet—that's some serious fire in the storytelling world. The premiere in Manila, held at the Missionary Training Center (MTC), was no small...

Decoding LRV: Smart Paint Choices for Your Home

Unraveling the Secrets of LRV Nobody thought analyzing paint meant diving into light reflectance values (LRV), but that's precisely where we're headed today. Painting a room seems simple until you realize your color choice might turn your bright haven into a cave or vice versa. Thanks to some insights from Wendy Anguiano in HelloNation, let's dig into this technical...

Nicely Network: Top Reddit Marketing for Big Brands

Reddit and AI: Nicely Network's Winning Formula Straight out of New York comes the latest scoop: Nicely Network's been crowned king of the Reddit jungle, earning the title of Best Reddit Marketing Agency for Enterprise Brands this November, courtesy of Better Business Advice. Now, if you've been paying any attention to how brands are grappling with the impossible search...

AI-Powered Bank Set to Transform Bahrain's Financial Landscape

A Fresh Approach to Banking in Bahrain The stuff that's stirring the pot in Bahrain’s financial sector right now? This big ol' partnership between Mumtalakat, the Kingdom's sovereign wealth fund, and ARP Group. They're on a mission to launch an AI-native wholesale bank smack dab in Bahrain. But here’s the kicker – they’ve got the green light, in principle at...